Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranquilon for Anxiety in Neurasthenia and Adjustment Disorders
NCT05586789Phase 3Completed
- Sponsor
- Valenta Pharm
- Start
- Oct 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ranquilon in neurasthenia, adjustment disorder (AD), sponsored by Valenta Pharm. Started Oct 2022; status: completed.
02
Drugs
ranquilon
03
Conditions
neurastheniaadjustment disorder (AD)
Beyond the preview
Go deeper on NCT05586789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05586789.